Erika Hamilton, Director of Breast Cancer Program at Sarah Cannon Research Institute, shared a post on X:
“Other excitement in ՛right sizing՛ is adding tucatinib and taking away chemo in neoadj HER2 BCSM…
TRAIN4 HP + tucatinib neoadjuvant 93% were able to omit chemo based on response pCR 73% without cytotoxic here!”
Other articles featuring Erika Hamilton on OncoDaily.